Phase 1/2 Dose-Escalation Study of TPI 287 in Combination with Bevacizumab in Adults with Recurrent Glioblastoma
One of the greatest challenges we face in brain tumor treatment is the inability to effectively deliver chemotherapy across the blood-brain barrier, our brain's natural defense. The technology used in this study seeks to overcome this dilemma by using the infective power of viruses not to cause disease but to harness the power of gene therapy. In recent years, JTCC has served as only one of ten leading centers nationwide to study Toca 511, a virus engineered to selectively infect and deliver a therapeutic gene only to brain tumor cells, while sparing surrounding healthy tissue. At the time of surgery, Toca 511 is injected into the wall surrounding the tumor cavity to infect any remaining tumor cells. Over the weeks to follow, patients take an oral medication, 5-flucytosine (5-FC), an antifungal drug that readily enters the brain. The infected tumor cells now carry genetic instructions for an enzyme that converts 5-FC into 5-fluorouracil (5-FU), a highly-potent chemotherapy that destroys cancer cells. Our early studies established that the treatment is safe, well tolerated, and infects tumor cells as intended, and our efforts in 2016 will be dedicated to studying the efficacy of Toca 511 in comparison to traditional chemotherapy.
Dr. Kaptain presented his work with Toca 511 in glioblastoma at the Annual Meeting of the Society for Neuro-Oncology in November 2015 in San Antonio.
Here are the three links of the abstracts that were published
DDEL-08OVERALL SAFETY AND EFFICACY IN SUBJECTS WITH RECURRENT HGG TREATED ACROSS 2 TOCAGEN STUDIES - PROGNOSTIC FACTORS ASSOCIATED WITH SURVIVAL
DDEL-06PRELIMINARY SAFETY OF TOCA 511, A RETROVIRAL REPLICATING VECTOR, IN PATIENTS WITH RECURRENT HIGH GRADE GLIOMA ACROSS THREE SEPARATE PHASE 1 STUDIES
SURG-10TRANSCRANIAL TOCA 511 FOLLOWED BY TOCA FC IN SUBJECTS WITH RECURRENT HIGH GRADE GLIOMA (HGG)